Abstract 54P
Background
Brain tumors are the most common tumors causing dysfunctions and the most fatal types of cancers. Patients with Parkinson’s disease (PD), the second most common neurodegenerative disorders, may be at high risk for brain tumors due to synucleins expression, chronic neuro-inflammation, levodopa therapy and radiations, but there is still controversy especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the risk of brain tumors in patients with PD in South Korea.
Methods
We analyzed 52,009 patients diagnosed with PD between 2010 and 2015, and the age- and sex-matched 260,045 individuals without PD (mean age: 71.3 years; 40.8% men), using the data from the Korean National Health Insurance Database. Patients previously diagnosed with cancer were excluded. The cohorts were followed up to 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the association between PD and brain cancer.
Results
Patients with PD had a higher brain cancer risk (hazard ratio [HR], 1.73; 95% confidence interval [CI], 1.05–2.85) in female patients with PD than in those without PD after adjustment for multiple covariates. There was no significant difference in brain tumor incidence between the two cohorts in men (HR, 1.02; 95% CI, 0.52-2.02).
Conclusions
This nationwide population-based cohort study revealed that patients with PD had higher risk of brain tumors than those without PD in Korea. Further studies are required to determine the underlying mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract